- Trial phase
- Pre-NDA (US drug application path; not a standard clinical phase)
- Time to market
- Unknown, and likely 2027 at the earliest: the NDA had not been confirmed as filed as of mid-2026, and a US approval decision would typically come roughly 10 months after a completed, accepted submission.
- Why 3/10
- No hard, dated catalyst is scheduled for Cingal in the next ~12 months: the NDA submission expected around Dec 31, 2025 (per the Nov 2025 10-Q) was still an open "timeline to monitor" as of the July 29, 2026 earnings update, and no PDUFA date exists in the data, a pre-NDA program that is one of several assets (Monovisc, Orthovisc, Hyalofast, Integrity) at a ~$200M company scores 3.
Watch Anika's Q3 2026 earnings call (next scheduled update) for a confirmation that the Cingal NDA was formally submitted and for FDA acceptance, that would finally give the stock a dated regulatory clock. Until a submission is confirmed, treat Cingal as a 2027+ US revenue story, not a near-term binary; near-term price action is being driven by the Q2 2026 earnings beat and guidance raise rather than by Cingal news.
Price Chart
Executive Summary
Cingal is Anika Therapeutics' (Nasdaq: ANIK, ~$19.28/share, ~$202M market cap) osteoarthritis pain-management product candidate heading to the US market via an NDA that requires two studies including a bioequivalence study; the NDA submission was expected around end-2025 per the Nov 2025 10-Q but remains an unconfirmed, unscheduled item as of the Q2 2026 earnings update. Cingal is one of five named products in Anika's portfolio (with Monovisc, Orthovisc, Hyalofast, Integrity), so the company's value does not ride on it alone.
How It Works
Cingal is Anika's single-injection product for osteoarthritis pain management. Under the US regulatory path described in the company's filings, it is being developed as a drug through an FDA NDA that requires completion of two studies including a bioequivalence study, a route that compares the product's absorption/profile against a reference rather than running a full-scale Phase 3-style efficacy program.
Trial Status
Per the Nov 5, 2025 10-Q (SEC catalyst record), the FDA's NDA path for Cingal requires completion of two studies, with bioequivalence study initiation on track for before year-end 2025; the NDA submission was expected around Dec 31, 2025 but no submission/acceptance was confirmed in the July 2026 earnings materials, and the stock showed essentially no reaction (+0.63% 1-day, -0.84% 5-day) around that expected submission date.
The Two-Sided Case
Upcoming Catalysts
- Confirmation of Cingal NDA submission + FDA acceptance (timing unscheduled, the key thing to watch on the Q3 2026 earnings call)
- Q3 2026 earnings call (next scheduled update) for Cingal NDA timeline guidance
- Hyalofast PMA FDA decision, related pipeline overhang that management removed from 2027 guidance
- Ongoing commercial-channel revenue momentum from Monovisc/Orthovisc and international sales
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Anika Therapeutics, Inc. 8-K ANIK ·Originating report